Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.69 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.66 |
| ▸ | CTSD | P07339 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198937 | 0.95 | BACE1 (0.73) | BACE1BACE2CTSD | |
| SCHEMBL29506418 | 0.94 | BACE1 (0.73) | BACE1BACE2CTSD | |
| SCHEMBL30567793 | 0.92 | BACE1 (0.67) | BACE1BACE2CTSD | |
| SCHEMBL30258973 | 0.92 | BACE1 (0.70) | BACE1BACE2CTSD | |
| SCHEMBL30607497 | 0.91 | BACE1 (0.66) | BACE1BACE2CTSD | |
| SCHEMBL30259249 | 0.90 | BACE1 (0.60) | BACE1BACE2CTSD | |
| SCHEMBL30354167 | 0.90 | BACE1 (0.57) | BACE1BACE2CTSD | |
| SCHEMBL29358485 | 0.89 | BACE1 (0.60) | BACE1BACE2CTSD | |
| SCHEMBL29871690 | 0.89 | BACE1 (0.55) | BACE1 | |
| SCHEMBL29514853 | 0.88 | BACE1 (0.58) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | claimed |
| US-20260092925-A1 | IMPROVED FLUORESCENT PROTEINS | NUCLERA LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-12516089-B2 | Bacteria based protein delivery | T3 PHARMACEUTICALS AG (CH) | 2026-01-06 | — | — | US | disclosed |
| US-20250382608-A1 | LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS | NUCLERA LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-12358955-B2 | Virulence attenuated bacteria based protein delivery | UNIVERSITAET BASEL (CH) | 2025-07-15 | — | — | US | disclosed |
| EP-4532730-A1 | LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS | Nuclera Ltd (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-12265082-B2 | Detecting microbial infection in wounds | SYNOVO GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| US-12209266-B2 | Generating nucleic acids with modified bases using recombinant terminal deoxynucleotidyl transferase | ILLUMINA, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240401065-A1 | Bacteria-Based Protein Delivery | UNIVERSITAET BASEL (CH) | 2024-12-05 | — | — | US | disclosed |
| US-12110516-B2 | Thermostable terminal deoxynucleotidyl transferase | ILLUMINA, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4150066-A1 | THERMOSTABLE TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE | Illumina, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4150065-A2 | GENERATING NUCLEIC ACIDS WITH MODIFIED BASES USING RECOMBINANT TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE | Illumina Inc (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11518789-B2 | Virulence attenuated bacteria based protein delivery | UNIVERSITAET BASEL (CH) | 2022-12-06 | — | — | US | disclosed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-2927312-B1 | APPARATUS FOR AUTOMATICALLY PREPARING CELL-FREE PROTEINS AND METHOD FOR PREPARING PROTEINS USING THE SAME | BIONEER CORP (KR) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022200492-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 PHARMACEUTICALS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022200493-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 PHARMACEUTICALS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022178020-A1 | VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF URINARY TRACT INFECTIONS | DUKE UNIVERSITY (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022090211-A1 | BACTERIA BASED PROTEIN DELIVERY | T3 PHARMACEUTICALS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| EP-3957645-A1 | VIRULENCE ATTENUATED BACTERIA BASED PROTEIN DELIVERY | Universität Basel (CH) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092925-A1 | IMPROVED FLUORESCENT PROTEINS | YIPF5, YIF1A, GTF3C5 | BACE1 3741/4885BACE2 3332/4885CTSD 1070/4885 |
| US-20250382608-A1 | LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS | RNGTT, RNMT, MRPS27 | BACE1 4536/4885BACE2 3949/4885CTSD 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.